Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)

Antonio Frassoldati, Valentina Guarneri, Federico Piacentini, Gordana Jovic, Simona Giovannelli, Cristina Oliva, Pier Franco Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a crosstalk with other growth factor-related transduction pathways (mainly epidermal growth factor receptor family related). The LETLOB study is a European multicenter, placebo-controlled, randomized phase II trial in postmenopausal patients with hormone-sensitive, HER2-negative, stage II-IIIA (T > 2 cm, N0-1, M0) breast cancer, in which letrozole or the combination of letrozole plus lapatinib will be administered for 6 months before surgery. Clinical endpoints (primary [ultrasonographic objective response], secondary [rate of pathologic complete response and of conservative surgery, safety, and time to treatment failure], and biologic [inhibition of intermediate and final biomarkers of the proliferative and apoptosis pathways and gene profile correlation with response]) will be evaluated.

Original languageEnglish
Pages (from-to)97-100
Number of pages4
JournalClinical Breast Cancer
Volume8
Issue number1
DOIs
Publication statusPublished - 2008

Keywords

  • Mitogen-activated protein kinase
  • Multigated acquisition scan
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)'. Together they form a unique fingerprint.

Cite this